Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

The axing of some 10,000 programs has consigned untold numbers of children and refugees to death, officials say. Documents ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

Older women with HIV face complex, intersectional challenges that warrant more support, according to a scoping review with ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...

The monologue-style drama is about a mother torn between love for her gay son and her conservative husband and faith ...